JP4723810B2 - ハイブリッド抗体 - Google Patents

ハイブリッド抗体 Download PDF

Info

Publication number
JP4723810B2
JP4723810B2 JP2003549500A JP2003549500A JP4723810B2 JP 4723810 B2 JP4723810 B2 JP 4723810B2 JP 2003549500 A JP2003549500 A JP 2003549500A JP 2003549500 A JP2003549500 A JP 2003549500A JP 4723810 B2 JP4723810 B2 JP 4723810B2
Authority
JP
Japan
Prior art keywords
antibody
sequence
sequences
framework
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003549500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511706A (ja
Inventor
ラッセル ロサー，
ダヤン ウー，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2005511706A publication Critical patent/JP2005511706A/ja
Application granted granted Critical
Publication of JP4723810B2 publication Critical patent/JP4723810B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2003549500A 2001-12-03 2002-12-03 ハイブリッド抗体 Expired - Fee Related JP4723810B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33659101P 2001-12-03 2001-12-03
US60/336,591 2001-12-03
PCT/US2002/038450 WO2003048321A2 (en) 2001-12-03 2002-12-03 Hybrid antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009092502A Division JP5054058B2 (ja) 2001-12-03 2009-04-06 ハイブリッド抗体

Publications (2)

Publication Number Publication Date
JP2005511706A JP2005511706A (ja) 2005-04-28
JP4723810B2 true JP4723810B2 (ja) 2011-07-13

Family

ID=23316785

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003549500A Expired - Fee Related JP4723810B2 (ja) 2001-12-03 2002-12-03 ハイブリッド抗体
JP2009092502A Expired - Fee Related JP5054058B2 (ja) 2001-12-03 2009-04-06 ハイブリッド抗体
JP2012056050A Withdrawn JP2012144551A (ja) 2001-12-03 2012-03-13 ハイブリッド抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009092502A Expired - Fee Related JP5054058B2 (ja) 2001-12-03 2009-04-06 ハイブリッド抗体
JP2012056050A Withdrawn JP2012144551A (ja) 2001-12-03 2012-03-13 ハイブリッド抗体

Country Status (12)

Country Link
US (1) US7399594B2 (https=)
EP (2) EP2298817A1 (https=)
JP (3) JP4723810B2 (https=)
AT (1) ATE550352T1 (https=)
AU (1) AU2002359568B2 (https=)
CA (1) CA2468744C (https=)
CY (1) CY1112843T1 (https=)
DK (1) DK1461428T3 (https=)
ES (1) ES2384100T3 (https=)
PT (1) PT1461428E (https=)
SI (1) SI1461428T1 (https=)
WO (1) WO2003048321A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7393648B2 (en) * 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
EP1521776A2 (en) * 2002-07-04 2005-04-13 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
KR101073590B1 (ko) * 2003-07-15 2011-10-14 메디뮨 리미티드 Ｉｌ-13에 대한 인간 항체 분자
AU2004290085A1 (en) * 2003-11-07 2005-05-26 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP1711527A4 (en) * 2003-12-15 2008-09-03 Dendreon Corp HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS
AU2005230868A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Method and apparatus for analyzing and generating human antibody amino acid and nucleic acid sequences
US20060263787A1 (en) * 2004-05-10 2006-11-23 Evans Glen A Immunoglobulin-like variable chain binding polypeptides and methods of use
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
BRPI0822099A2 (pt) * 2007-12-21 2017-05-23 Medimmune Ltd membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
EP2254909A4 (en) * 2007-12-21 2012-05-02 Ca Nat Research Council NON-AGGREGATING HUMANS VH DOMAINS
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20110313134A1 (en) * 2008-11-06 2011-12-22 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
WO2010110838A2 (en) * 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
BR112012022342A2 (pt) * 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
DK3323830T3 (da) 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
MX375569B (es) 2017-02-08 2025-03-04 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
DK3668874T3 (da) 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepin-konjugater
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR102890251B1 (ko) 2019-03-15 2025-11-25 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
ATE245703T1 (de) 1992-09-22 2003-08-15 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
EP0888125B1 (en) * 1996-03-20 2004-05-26 Immunomedics, Inc. GLYCOSYLATED IgG ANTIBODIES
US5908925A (en) * 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EP1436329A4 (en) 2001-09-20 2005-04-27 Alexion Pharma Inc ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules

Also Published As

Publication number Publication date
AU2002359568A1 (en) 2003-06-17
EP2298817A1 (en) 2011-03-23
JP5054058B2 (ja) 2012-10-24
JP2009153527A (ja) 2009-07-16
ES2384100T3 (es) 2012-06-29
DK1461428T3 (da) 2012-06-04
CA2468744C (en) 2013-05-14
CY1112843T1 (el) 2016-02-10
ATE550352T1 (de) 2012-04-15
US20030219861A1 (en) 2003-11-27
JP2012144551A (ja) 2012-08-02
US7399594B2 (en) 2008-07-15
PT1461428E (pt) 2012-05-29
WO2003048321A3 (en) 2003-10-16
CA2468744A1 (en) 2003-06-12
EP1461428A4 (en) 2005-05-25
JP2005511706A (ja) 2005-04-28
WO2003048321A2 (en) 2003-06-12
EP1461428A2 (en) 2004-09-29
EP1461428B1 (en) 2012-03-21
AU2002359568B2 (en) 2008-02-21
SI1461428T1 (sl) 2012-07-31

Similar Documents

Publication Publication Date Title
JP4723810B2 (ja) ハイブリッド抗体
US7927817B2 (en) Hybrid antibodies
ES2429541T3 (es) Intercambio de casete de región variable de inmunoglobulina
CN100415765C (zh) 兔单克隆抗体的人源化方法
US20110313134A1 (en) Engineered antibodies with reduced immunogenicity and methods of making
US20040086979A1 (en) Humanized rabbit antibodies
JP2016216461A (ja) ヒト化抗体
WO2009132287A2 (en) Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
WO2014100542A1 (en) High-throughput antibody humanization
Lai et al. Synthetic Antibody Engineering: Concepts and Applications
Rouet Mutational, structural and evolutionary analyses of the human antibody VL domain

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101012

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110223

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110317

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110408

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140415

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees